InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by M. Pykett, Director. Officer active across 1 companies, notably Pharming Group N.V.. In total, 16 reports have been logged. The latest transaction was disclosed on 10 June 2025 — Purchase. Regulator: AFM. All data is accessible without signup.
Declarations16 total
031,400 shares0
Gewoon aandeel
AFM:176245·
Ideal exit: 7 Mar 2026 (T+270)
08,487 shares0
Gewoon aandeel
AFM:165348·
Ideal exit: 28 Jul 2025 (T+270)
08,487 shares0
Gewoon aandeel
AFM:161781·
Ideal exit: 28 Apr 2025 (T+270)
09,553 shares0
Gewoon aandeel
AFM:159038·
Ideal exit: 23 Feb 2025 (T+270)
07,419 shares0
Gewoon aandeel
AFM:155755·
Ideal exit: 10 Dec 2024 (T+270)
07,234 shares0
Gewoon aandeel
AFM:149885·
Ideal exit: 27 Jul 2024 (T+270)
07,234 shares0
Gewoon aandeel
AFM:146141·
Ideal exit: 29 Apr 2024 (T+270)
07,446 shares0
Gewoon aandeel
AFM:143211·
Ideal exit: 18 Feb 2024 (T+270)
07,022 shares0
Gewoon aandeel
AFM:138775·
Ideal exit: 16 Dec 2023 (T+270)
€9,1749,760 shares@ €0.940.0012% mcap11.8% of flow
Gewoon aandeel
AFM:132723·
Ideal exit: 24 Jul 2023 (T+270)
€7,5009,760 shares@ €0.76850.0010% mcap9.6% of flow
Gewoon aandeel
AFM:128013·
Ideal exit: 1 May 2023 (T+270)
€7,1479,300 shares@ €0.76850.0009% mcap9.2% of flow
Gewoon aandeel
AFM:125088·
Ideal exit: 19 Feb 2023 (T+270)
€7,49910,220 shares@ €0.73380.0010% mcap9.6% of flow
Gewoon aandeel
AFM:122172·
Ideal exit: 19 Dec 2022 (T+270)
€7,5007,241 shares@ €1.03580.0010% mcap9.6% of flow
Gewoon aandeel
AFM:116792·
Ideal exit: 25 Jul 2022 (T+270)
€15,44214,909 shares@ €1.03580.0020% mcap19.8% of flow
Gewoon aandeel
AFM:114817·
Ideal exit: 2 May 2022 (T+270)
€23,55921,997 shares@ €1.0710.0030% mcap30.3% of flow
Gewoon aandeel
AFM:108690·
Ideal exit: 19 Dec 2021 (T+270)
16 of 16 declarations
About M. Pykett
M. Pykett is a board member at Pharming Group N.V. He plays an active role in the governance of the company, which focuses on biopharmaceutical solutions. His expertise in the sector is crucial for Pharming's strategic decisions.
